CIC
VKTX icon

Cornercap Investment Counsel’s Viking Therapeutics VKTX Stock Holding History

Cornercap Investment Counsel’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-41,820
Closed -$121K – 630
2022
Q2 		$121K Buy
+41,820
New +$103K 0.02% 523

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cornercap Investment Counsel's VKTX Position: Q3 2022 in Review

Cornercap Investment Counsel sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 41,820 shares — an estimated $121K sold.

Cornercap Investment Counsel first reported a position in VKTX in Q2 2022 and held it in 1 quarter. The position peaked at $121K in Q2 2022. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

  • Cornercap Investment Counsel reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 41,820 Viking Therapeutics shares in Q3 2022, an estimated $121K.
  • Cornercap Investment Counsel first reported a position in Viking Therapeutics in Q2 2022 and held it in 1 quarter.
  • Cornercap Investment Counsel's Viking Therapeutics position peaked at $121K in Q2 2022.
  • 107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on Cornercap Investment Counsel's 13F filing for Q3 2022, filed 14 Nov 2022.